Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study

Sherko Kuemmel(Humboldt-Universität zu Berlin), Miguel Martín(Hospital General Universitario Gregorio Marañón), Bartosz Itrych(Centralny Szpital Kliniczny), Carlo Tondini(Ospedale Papa Giovanni XXIII), Servando Cardona‐Huerta(Tecnológico de Monterrey), Zbigniew Nowecki(The Maria Sklodowska-Curie National Research Institute of Oncology), Marco Sequi(Roche (Switzerland)), Eleonora Restuccia(Roche (Switzerland)), Erika Hitre(National Institute of Oncology), Bogusława Karaszewska(State University of Applied Sciences in Konin), José Manuel Pérez-García(MedSIR (Spain)), Flavia Morales-Vásquez(Secretaria de Salud), Jacinta Abraham(Velindre NHS Trust), Estefanía Monturus(Roche (Switzerland)), Mark Benyunes(Roche (Switzerland)), Alejandro Juárez-Ramiro
Breast Cancer Research and Treatment
March 21, 2021
10.1007/s10549-021-06145-3
Cited by 23

Related Papers

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
|The Lancet|2020|1.8k
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
|New England Journal of Medicine|2019|1.4k